Cefprozil

證據等級: L5

預測適應症: 10 個

Cefprozil: From Respiratory and Skin Infections to Urinary Tract Infection

One-Sentence Summary

Cefprozil is an oral second-generation cephalosporin antibiotic primarily known for treating upper respiratory tract infections (pharyngitis, acute bronchitis, sinusitis) and skin/soft tissue infections, though it is not currently registered in Taiwan. The TxGNN model predicts it may be effective for Urinary Tract Infection (UTI), with 0 registered clinical trials and 9 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Upper respiratory tract infections, skin/soft tissue infections (not registered in Taiwan)
Predicted New Indication	Urinary Tract Infection
TxGNN Prediction Score	99.99%
Evidence Level	L2
Taiwan Market Status	✗ Not Marketed
Number of Licenses	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from the DrugBank record in this Evidence Pack. Based on established pharmacological knowledge, Cefprozil belongs to the second-generation cephalosporin class and works by inhibiting bacterial cell wall synthesis — it binds to penicillin-binding proteins (PBPs) on the bacterial membrane, disrupting peptidoglycan cross-linking and ultimately causing cell lysis. This beta-lactam mechanism is the same one that underpins the entire cephalosporin family’s antibacterial efficacy.

What makes the UTI prediction particularly compelling is Cefprozil’s coverage of the most common uropathogens. In vitro studies — including a Taiwan-based study — confirm that Cefprozil inhibits over 80% of Escherichia coli and Klebsiella pneumoniae clinical isolates at achievable concentrations, and it is also active against Proteus mirabilis. Together, these three organisms account for the large majority of community-acquired UTIs. Critically, oral Cefprozil achieves high urinary drug concentrations after absorption, which is the key pharmacokinetic requirement for effective UTI treatment.

Three independent randomized comparative trials from the early 1990s directly tested Cefprozil against cefaclor (a reference second-generation cephalosporin with an established UTI indication) and found comparable clinical cure rates of approximately 93–94% in patients with acute uncomplicated UTI. This body of evidence, combined with the mechanistic rationale and favorable oral pharmacokinetics, strongly supports the TxGNN prediction. It is also worth noting that Cefprozil holds FDA approval for UTI treatment in the United States — confirming that this “repurposing” prediction aligns with an internationally recognized clinical use.

Clinical Trial Evidence

Currently no related clinical trials registered for Cefprozil in urinary tract infection.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
1761453	1991	Comparative RCT	J Antimicrobial Chemother	Open-label RCT in 102 adults; Cefprozil 500 mg QD vs. cefaclor 250 mg TID × 10 days for acute uncomplicated UTI — clinical efficacy comparable between groups
1952874	1991	Comparative RCT	Antimicrob Agents Chemother	108 college women with acute UTI; Cefprozil QD vs. cefaclor TID × 10 days; clinical cure 94% vs. 94%, bacterial cure 93% vs. 94% — not significantly different
1611652	1992	Comparative RCT	Clinical Therapeutics	Multicenter RCT in patients ≥2 years with acute uncomplicated UTI; satisfactory clinical response rates comparable between Cefprozil QD and cefaclor TID over 10 days
7681376	1993	Systematic Review	Drugs	Comprehensive review of Cefprozil’s antibacterial activity and therapeutic profile; confirms clinically relevant spectrum against E. coli, Klebsiella, and other Enterobacteriaceae relevant to UTI
1494237	1992	Clinical Study (Pediatric)	Jpn J Antibiotics	Pediatric PK study with multiple doses; measured serum and urinary concentrations confirming adequate urinary drug levels for UTI coverage
1289583	1992	Clinical Study (Pediatric)	Jpn J Antibiotics	21 pediatric patients with bacterial infections including 3 UTI cases; good-to-excellent clinical response in 19/21 patients with complete bacterial eradication
8464648	1993	Drug Review	Pediatric Annals	Review of Cefprozil’s oral bioavailability, PK characteristics, and tolerability; confirms potential role in UTI management alongside respiratory and skin infections
8042575	1994	Review	Am Family Physician	Comparative review of newer oral cephalosporins; Cefprozil confirmed as effective (though costly) alternative for skin, respiratory, and urinary tract infections with convenient dosing
8529432	1995	In Vitro Study	Chemotherapy	Taiwan-based in vitro study on 637 clinical isolates; Cefprozil inhibited >80% of E. coli and K. pneumoniae at 8 mg/L — directly supports local uropathogen coverage

Taiwan Market Information

Cefprozil is currently not registered in Taiwan (TFDA). No product licenses, approved indications, or dosage forms are on file. For reference, Cefprozil is marketed in the United States under the brand name Cefzil and holds FDA approval for UTI, pharyngitis/tonsillitis, acute bronchitis, acute bacterial exacerbation of chronic bronchitis, and uncomplicated skin/soft tissue infections.

Safety Considerations

Safety data (warnings, contraindications, drug-drug interactions) was not retrievable from the local TFDA database, as Cefprozil is not registered in Taiwan, and no DDI records were identified through available databases.

Please refer to the US FDA-approved prescribing information (Cefzil label) for full safety information, including guidance on penicillin/cephalosporin hypersensitivity, Clostridioides difficile-associated diarrhea risk, and use in renal impairment.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Three independent comparative RCTs — conducted across multiple centers, enrolling over 200 patients — consistently demonstrate that Cefprozil achieves clinical and bacteriological cure rates in acute uncomplicated UTI that are statistically equivalent to the reference standard cefaclor (~93–94%). The mechanistic basis is solid (PBP inhibition, high urinary drug concentrations, direct activity against E. coli, Klebsiella, and Proteus), and the indication is already approved by the US FDA. The primary barrier is the absence of Taiwan TFDA registration, not a lack of clinical evidence.

To proceed, the following is needed:

Regulatory pathway assessment: Determine whether to pursue a new TFDA drug license application or rely on import for specific patient populations
Full safety dossier: Obtain the FDA-approved US prescribing information (Cefzil label) for complete warnings, contraindications, and drug interaction data
Local resistance surveillance review: Evaluate Taiwan AMR surveillance data (TSAR programme) to confirm that contemporary local E. coli and Klebsiella susceptibility rates remain adequate for empiric UTI treatment
Updated clinical evidence: All available RCTs are from 1991–1995; a gap analysis should assess whether newer comparative data or guideline endorsements exist
Renal dosing guidance: Confirm dose-adjustment protocols for patients with renal impairment, which is critical for UTI patients who often have underlying renal comorbidities
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.